Targeting immune system 'cuts cardiac death risk'

Modifying the immune system of heart failure patients could cut their risk of death and hospitalisation for a cardiac event, suggest US research findings

Non-specific immunomodulation therapy (IMT) was shown to benefit patients who had no history of a previous MI or who had mild heart failure defined as suffering fatigue, palpitation or dyspnoea on ordinary physical exertion.

For the study, 2,426 patients with heart failure were randomly assigned to IMT or placebo on days one, two, 14 and every 28 days thereafter. All patients were treated for a minimum of 22 weeks.

For IMT, a venous blood sample is taken from the patient and exposed to oxidative stress. Once injected back into the patient, apoptosis of leukocytes is triggered, which in turn leads to a reduction in inflammatory cytokines and an increase in non-inflammatory cytokines.

Key to the theory behind this technique is that inflammation associated with heart failure has been linked to both aspects of the cytokine network.

rachel.liddle@haymarket.com

The Lancet

Comment below and tell us what you think

See all commented articles in our Forums and Blogs section

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus